Wyeth names new chief executive
pharmafile | October 10, 2007 | News story | Sales and Marketing | Pfizer, Wyeth
Wyeth will begin 2008 with a new leader at the helm.
Bernard Poussot will become the company's elected president and chief executive from 1 January, 2008, after 22 years at Wyeth.
Mr Poussot will take over from Robert Essner, who has held the top job since 2001 and intends to see the year out.
Essner said: "The election of Mr Poussot is a result of the company's ongoing succession management process that has been an important focus of the Wyeth board of directors and management. Bernard is exceptionally well-qualified for this role, and we have built a world-class management team to support him and the company."
Poussot began his career at Wyeth in 1986. Ten years later, in 1996, he was appointed president of Wyeth-Ayerst International, and the following year was promoted to president of the worldwide pharmaceutical business. He was then promoted once again in 2002, becoming executive vice president, Wyeth, a role in which he took on responsibility for the company's R&D, before becoming president and vice chairman, Wyeth, in April 2006 and then president, chief operating officer and vice chairman, Wyeth, in January this year.
Bernard Poussot's appointment comes as GSK also announces its next chief executive, Andrew Witty, who will replace JP Garnier in May 2008.
Witty, who joined the company in 1985, pipped two other GSK senior employees to his new post.
Like Wyeth, GlaxoSmithKline puts merit on recruiting internally, and both have selected candidates with more than two decades' experience within their respective companies.
GSK's chairman Sir Christopher Gent said: "The fact that we have been able to select a successor to JP from three strong internal candidates is a testament to the quality of management at GSK."
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
